US Subpoena For Sun Amid Pricing Heat
US lawmakers continue to scrutinize drug firms amid ongoing concerns over price-related issues and their impact on healthcare costs. The US Justice Department’s antitrust division has subpoenaed Sun Pharma for information pertaining to generic drugs, pricing and certain company records, though the Indian firm claimed the move would have no immediate impact on its earnings.
You may also be interested in...
Ok, now for the Indian industry's take on why generic prices may have surged in the US, against the backdrop of the probe by Senator Bernie Sanders and Representative Elijah Cummings. Put simply, much of the Indian defense can be read as: You brought this upon yourself.
The US Supreme Court is starting off its 2014-15 session with yet another patent case involving biopharmaceutical companies – this time Teva and its money-maker multiple sclerosis drug Copaxone (glatiramer acetate), whose last remaining patent was declared invalid by the US Court of Appeals for the Federal Circuit in July 2013.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.